Skip to content

Tomographic Comparison of Aerosol Lung Distribution With Two Nebulizers Through a High Flow Nasal Cannula

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02429817
Enrollment
6
Registered
2015-04-29
Start date
2015-04-30
Completion date
2016-12-31
Last updated
2016-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Pulmonary aerosol distribution, SPECT-CT analysis, High flow nasal cannula, Vibrating-mesh nebulizer, Jet nebulizer

Brief summary

Vibrating-mesh nebulizers ensure currently the best deposition output and are recommended in routine use in intensive care unit. However, jet nebulizers remain the most frequently used nebulizers. On a bench study, aerosol delivery through a high flow nasal cannula (HFNC) was increased using a vibrating-mesh nebulizer as compared to a jet nebulizer. Lung distribution of nebulized particles delivered through a HFNC has never been investigated in vivo. The aim of this study was to compare aerosol lung distribution with both nebulizers through a HFNC by SPECT-CT.

Interventions

OTHERSingle photon emission computed tomography

Imaging technique to investigate lung aerosol distribution

OTHERSpirometry

FEV1, FVC assessment

99mTc-DTPA solution placed on the nebulizer reservoir

Sponsors

Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy respiratory function

Exclusion criteria

* Pulmonary disease

Design outcomes

Primary

MeasureTime frameDescription
Pulmonary depositionImmediately after nebulization by imaging technique, expected average of 15 minutesSingle photon emission tomography combined with a CT-scan

Secondary

MeasureTime frame
Three-dimensional penetration indeximmediately after the nebulization by imaging assessment, expected average of 30 minutes

Other

MeasureTime frame
SpirometryBaseline

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026